我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

长期口服他汀类药物与急性ST段抬高型心肌梗死经皮冠状动脉介入治疗预后的相关性

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2015年第4期
页码:
434-436
栏目:
临床研究
出版日期:
2015-04-20

文章信息/Info

Title:
Prognostic value of statins on 1-year major adverse cardiac events in ST-elevated myocardial infarction after percutaneous coronary intervention
作者:
郎立国; 李振军; 孙荣亮; 栾 红; 葛利军
(宁夏回族自治区人民医院心血管内科，宁夏 银川 750004)
Author(s):
LANG Li-guo;  LI Zhen-jun;  SUN Rong-liang;  LUAN Hong;  GE Li-jun
(Department of Cardiology, People’s Hospital, Ningxia Hui Autonomous Region, Yinchuan 750004, Ningxia, China)
关键词:
他汀类药物; 急性ST段抬高性心肌梗死; 经皮冠脉介入治疗; 主要心脑血管不良事件
Keywords:
statins;  ST-elevated myocardial infarction;  percutaneous coronary intervention;  cardiovascular and cerebrovascular events
分类号:
R541.61
DOI:
-
文献标识码:
A
摘要:
目的 探讨长期口服他汀类药物与急性ST段抬高型心肌梗死（STEMI）行急诊经皮冠脉介入（PCI）治疗患者预后的关系。方法 选择STEMI行急诊PCI患者301例，根据长期是否服用他汀类药物分为未服组(198例)和服用组(103例)。对患者随访1年，观察主要心脑血管不良事件（MACCE）发生率。并对各因素采用Logistic回归分析。结果 未服用组MACCE发生率〔50/198(25.3%)〕显著高于服用组〔14/103(13.6%)〕（P<0.05）,主要表现在再发心绞痛〔36/198(18.2%) vs. 7/103(6.8%)，P<0.01〕和再次住院〔40/198(20.2%) vs. 9/103(8.7%)，P<0.01〕。多因素Logistic回归分析示长期服用他汀类药物是一个保护因子（OR 0.24，95%CI 0.10-0.55，P<0.01）。结论 长期服用他汀类药物可降低STEMI行急诊PCI患者1年MACCE的发生率,是一个保护因子。
Abstract:
AIM To investigate the relationship between long-term statin pretreatment and 1-year major adverse cardiac events in patients with ST-elevated myocardial infarction (STEMI) after percutaneous coronary intervention (PCI). METHODS Three hundred and one STEMI patients were divided into group A (no long-term statin pretreatment, n=198) and group B (long-term statin pretreatment, n=103). Patients were followed-up for 1 year and clinical data and cardiovascular and cerebrovascular events (MACCE) were analyzed. The independent effect of variables on the prognosis was calculated using binary logistic regression analysis. RESULTS MACCE rate was higher in group A than in group B (P<0.05). This difference resulted from recurrent angina (P<0.01) and rehospitalization (P<0.01). In binary logistic regression analysis, long-term statin pretreatment was a protective factor in STEMI patients after PCI (OR 0.24, 95%CI 0.10-0.55, P<0.01). CONCLUSION Long-term statin pretreatment can reduce 1-year MACCE rate in STEMI patients after PCI and is a protective factor.

参考文献/References

[1]张瑞生,季福绥,何青,等.强化阿托伐他汀对冠状动脉介入治疗的心肌保护作用[J].中国心血管杂志,2008,13(3):191-194.
[2]伍方红,许得泽,韦继政,等.负荷量阿托伐他汀对不稳定型心绞痛患者冠状动脉介入治疗后近期心血管事件的影响[J].岭南心血管病杂志,2013, 19(3):293-297.
[3]许 敏,郭金成,王国忠,等.急诊冠状动脉介入术强化阿托伐他汀治疗的临床疗效[J].临床心血管病杂志,2013,29(1):17-20.
[4]王晓华,刘树琴,王英丽,等.强化阿托伐他汀对老年非ST段抬高型急性冠脉综合征患者介入术中的心肌保护作用[J].实用临床医药杂志,2013,17(15):14-16.
[5]杨树森,甘润韬,孙延明,等.阿托伐他汀对ST段抬高型急性心肌梗死患者急诊PCI术后无复流现象的影响[J].临床心血管病杂志,2011,27(1):35-38.
[6]Lev EI,Kornowski R,Vaknin AH,et al.Effevt of previous treatment with statinson outcome of patients with ST segment elevation mycardial infarcation treated with primary percutaneous coronary intervention[J].Am J Cardiol,2009,103(2):165-169.
[7]邓峰峰,张建华,汪跃国,等.冠状动脉介入治疗术术前短期强化降脂对冠心病围手术期心肌梗死影响的Meta分析[J].中华临床医师杂志(电子版),2013,7(14):6514-6518.
[8]Di Sciascio G,Patti G,Pasceri V,et al.Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention:results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial[J].J Am Coll Cardiol,2009,54(6):558-565.

备注/Memo

备注/Memo:
收稿日期：2014-09-11.
通讯作者：葛利军，主任医师，主要从事冠心病介入治疗研究 Email：gelijun1958@126.com
作者简介：郎立国，硕士生 Email：549450441@qq.com
更新日期/Last Update: 2015-04-22